Clinical data shows significant weight loss at 10 mg and 12.5 mg
1 Cardiovascular and metabolic diseases, including obesity, remain important areas of unmet medical need, and we plan to continue applying our global capabilities to advance a pipeline of investigational treatments that have the potential to fill critical gaps in patient care, including continued development of our oral GIPR antagonist candidate and other earlier obesity programs, Chris Boshoff, MD, PhD, chief scientific officer and president of Research and Development at Pfizer, said in a news release
Female: Interaction with estrogen-driven tissues
The solution should always be clear and colourless or almost colourless
Bake for 10-12 minutes or until edges are golden brown
Can I continue receiving the drug after the trial ends